key: cord-0888518-9le4oeae
authors: Choi, Hyun-Woo; Jeon, Chae-Hyeon; Won, Eun Jeong; Kang, Seung-Ji; Lee, Seung Yeob; Kee, Seung-Jung
title: Performance of Severe Acute Respiratory Syndrome Coronavirus 2 Serological Diagnostic Tests and Antibody Kinetics in Coronavirus Disease 2019 Patients
date: 2022-04-14
journal: Front Microbiol
DOI: 10.3389/fmicb.2022.881038
sha: 05d9d71cee3a7896481c1929f0a8bdff414102e8
doc_id: 888518
cord_uid: 9le4oeae

Serological testing is recommended to support the detection of undiagnosed coronavirus disease 2019 (COVID-19) cases. However, the performance of serological assays has not been sufficiently evaluated. Hence, the performance of six severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binding antibody assays [three chemiluminescence (CLIAs) and three lateral flow immunoassays (LFIAs)] and a surrogate virus neutralization test (sVNT) was analyzed in a total of 988 serum samples comprising 389 COVID-19-positives and 599 COVID-19-negatives. The overall diagnostic sensitivities of CLIAs and LFIAs ranged from 54.2 to 56.6% and from 56.3 to 64.3%, respectively. The overall diagnostic specificities of CLIAs and LFIAs ranged from 98.2 to 99.8% and from 97.3 to 99.0%, respectively. In the symptomatic group (n = 321), the positivity rate increased by over 80% in all assays > 14 days after symptom onset. In the asymptomatic group (n = 68), the positivity rate increased by over 80% in all assays > 21 days after initial RT-PCR detection. In LFIAs, negatively interpreted trace bands accounted for the changes in test performance. Most false-positive results were weak or trace reactions and showed negative results in additional sVNT. For six binding antibody assays, the overall agreement percentages ranged from 91.0 to 97.8%. The median inhibition activity of sVNT was significantly higher in the symptomatic group than in the asymptomatic group (50.0% vs. 29.2%; p < 0.0001). The median times to seropositivity in the symptomatic group were 9.7 days for CLIA-IgG, 9.2 and 9.8 days for two CLIAs-Total (IgM + IgG), 7.7 days for LFIA-IgM, 9.2 days for LFIA-IgG, and 8.8 days for sVNT-IgG, respectively. There was a strong positive correlation between the quantitative results of the four binding antibody assays and sVNT with Spearman ρ-values ranging from 0.746 to 0.854. In particular, when using LFIAs, we recommend using more objective interpretable assays or establishing a band interpretation system for each laboratory, accompanied by observer training. We also anticipate that sVNT will play an essential role in SARS-CoV-2 antibody testing and become the practical routine neutralizing antibody assay.

Serological testing is recommended to support the detection of undiagnosed coronavirus disease 2019 cases. However, the performance of serological assays has not been sufficiently evaluated. Hence, the performance of six severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binding antibody assays [three chemiluminescence (CLIAs) and three lateral flow immunoassays (LFIAs)] and a surrogate virus neutralization test (sVNT) was analyzed in a total of 988 serum samples comprising 389 COVID-19-positives and 599 COVID-19-negatives. The overall diagnostic sensitivities of CLIAs and LFIAs ranged from 54.2 to 56.6% and from 56.3 to 64.3%, respectively. The overall diagnostic specificities of CLIAs and LFIAs ranged from 98.2 to 99.8% and from 97.3 to 99.0%, respectively. In the symptomatic group (n = 321), the positivity rate increased by over 80% in all assays > 14 days after symptom onset. In the asymptomatic group (n = 68), the positivity rate increased by over 80% in all assays > 21 days after initial RT-PCR detection. In LFIAs, negatively interpreted trace bands accounted for the changes in test performance. Most false-positive results were weak or trace reactions and showed negative results in additional sVNT. For six binding antibody assays, the overall agreement percentages ranged from 91.0 to 97.8%. The median inhibition activity of sVNT was significantly higher in the symptomatic group than in the asymptomatic group (50.0% vs. 29.2%; p < 0.0001). The median times to seropositivity in the symptomatic group were 9.7 days for CLIA-IgG, 9.2 and 9.8 days for two CLIAs-Total (IgM + IgG), 7.7 days for LFIA-IgM, 9.2 days for LFIA-IgG, and

Coronavirus disease 2019 , caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in December 2019 and has become a pandemic with continued transmission (Fong et al., 2020; Wu and McGoogan, 2020) . In Korea, the first COVID-19 case was confirmed in January 2020 (Korea Centers for Disease Control and Prevention, 2021) . The Korean government has wisely established a strategy against COVID-19 consisting of swift implementation of in vitro diagnostic (IVD) devices in disease prevention and control sites, early and extensive testing using accurate realtime reverse transcriptase-polymerase chain reaction (RT-PCR) testing, systematic contact tracing, and quarantine measures (Ministry of Food and Drug Safety, 2021) . Therefore, it is conceivable that the proportion of undetected patients with COVID-19 is minimal (Song et al., 2020) . Nonetheless, it is possible that the undiagnosed cases, including asymptomatic patients and symptomatic patients who visit the hospital later in disease and who test negative by molecular assays, may impede the effective control of disease spread Zhang et al., 2021) . Hence, serological testing is recommended to support the detection of such undiagnosed cases (Guo et al., 2020) . Serological testing is also essential for surveys to know the epidemic curve and set the surveillance strategy, integral to pandemic control measures. Furthermore, serologic testing helps determine antibody kinetics to predict the infection severities and outcomes in SARS-CoV-2 infection. Combined with RT-PCR, detection of the production of immunoglobulin (Ig) class can be a valuable tool to enhance sensitivity and accuracy for the detection of COVID-19. Few studies have evaluated the seroconversion of IgG or M using several commercial serologic assays (Guo et al., 2020; Orner et al., 2021) .

Several types of assays have been developed for the detection of SARS-CoV-2 antibodies. As of September 9, 2021, the Korean Ministry of Food and Drug Safety approved 62 COVID-19 diagnostic reagents, including 28 PCR assays, 20 antigen assays, and 14 antibody assays (Innovative and Diagnostic Medical Device Policy Division, 2021). Among the 14 antibody assays, seven are lateral flow immunoassays (LFIAs), five are enzyme-linked immunosorbent assays (ELISAs), and two are chemiluminescent immunoassays (CLIAs). LFIAs, usually used at the point of care, detect antibodies using immunochromatographic chemistry. Manual or semiautomated 96-well ELISAs and fully automated CLIA/chemiluminescent microparticle immunoassays (CMIAs) are available to measure specific antibody subclasses such as IgA, M, and G . Most SARS-CoV-2 serologic assays have been developed to target antibodies for one of the two structural proteins: the most surface-exposed spike (S) protein that comprises S1 and S2 functional subunits or the most abundantly expressed nucleocapsid (N) protein. In addition, the receptor-binding domain (RBD), which is located in the S1 subunit and mediates viral entry, is a target for detecting SARS-CoV-2 antibodies (Satarker and Nampoothiri, 2020; Tai et al., 2020; Walls et al., 2020) . Antibodies can be classified into two categories according to their responses to the virus: binding antibodies (bAbs) and neutralizing antibodies (nAbs). The bAbs act against the virus-infected cells via complement activation or opsonization; on the other hand, the nAbs bind to the viral structures that block viral attachment and entry for viral replication (Klasse, 2014; Zhang et al., 2021) . The gold standard for detecting nAbs against SARS-CoV-2 is the conventional plaque reduction neutralization test, for which any live pathogen and biosafety level (BSL) 3 facility are essential, making routine evaluation difficult. Recently, an ELISA-based surrogate virus neutralization test (sVNT) designed to mimic the virus-host interaction using purified RBD and angiotensin-converting enzyme 2 (ACE2) was developed, which can be performed within 1-2 h in an ordinary BSL2 laboratory (Klasse, 2014; Tan et al., 2020) . However, the performance and usefulness of serological assays for detecting SARS-CoV-2 bAbs or nAbs have not yet been thoroughly assessed. Here, we evaluated the diagnostic performance of seven SARS-CoV-2 serologic assays-six bAb assays and one nAb assay. Furthermore, we investigated the dynamic characteristics of the immune responses in patients with COVID-19.

A total of 988 serum samples were obtained from 786 patients, consisting of 199 COVID-19-positive patients confirmed using RT-PCR between March and November 2020, and 587 COVID-19-negative patients with no history of COVID-19 or any epidemiological relationship with COVID-19 between June 2019 and October 2020 at Chonnam National University Hospital (CNUH), Gwangju, South Korea. RT-PCR was performed using 

The sensitivity [true positive/(true positive + false negative)], specificity [true negative/(false positive + true negative)], positive predictive value [PPV: sensitivity × prevalence/ (sensitivity × prevalence + (1 -specificity) × (1 − prevalence))], negative predictive value [NPV: specificity × (1 − prevalence)/((1 − sensitivity) × prevalence + specificity × (1 − prevalence))], and accuracy [sensitivity × prevalence + specificity × (1prevalence)] for the three CLIAs and three LFIAs were calculated based on RT-PCR results and the history of COVID-19 or epidemiological relationship with COVID-19. For LFIAs, the separated and combined results of IgM and IgG were included in the performance analysis. The detection rates of SARS-CoV-2 antibody assays in known COVID-19-positive samples were assessed based on the number of days post symptom onset in the symptomatic group and the number of days post the initial positive RT-PCR detection in the asymptomatic group. The degree of agreement between assays was quantified using the agreement percentage and Cohen's kappa (κ) value and further evaluated by McNemar's test of asymmetry (McHugh, 2012; Perkmann et al., 2020) . The Fisher's exact test was performed to calculate p-values for differences in proportions between assays. Normality tests were performed using the D'Agostino-Pearson test. The Mann-Whitney U-test was used to compare assay level results based on the number of days post symptom onset. The Spearman correlation coefficient (ρ) was used to measure the strength and direction of the correlation between four bAb assays vs. sVNT (Laerd Statistics, 2020) . Statistical significance was set at p < 0.05. All statistical analyses were performed using the MedCalc Diagnostic Test Evaluation Calculator 1 and GraphPad Prism software (version 5.03).

The clinical and demographic characteristics of the patients and samples used in this study are summarized in showing that about one or two samples per week were collected as follows: the first samples (patient number = 97) were collected at 2 days post the diagnosis of COVID-19; the second (n = 97) at 9 days; the third (n = 49) at 12 days; the fourth (n = 22) at 17 days; the fifth (n = 10) at 18.5 days; the sixth (n = 4) at 16 days; the seventh (n = 3) at 19 days; the eighth (n = 3) at 23 days; and the ninth (n = 2) at 28.5 days (Supplementary Table 1 ). The median number of multiple samples given by the same patient was three. Of the 389 positive samples, 321 (82.5%) and 68 (17.5%) were obtained from 158 symptomatic and 41 asymptomatic COVID-19 patients, respectively. Of the 599 samples from COVID-19-negative patients, most (96.5%) were one sample per patient; 144 (24%) were collected during the pre-pandemic period from June 2019 to November 2019, which were all antinuclear antibody (ANA)-positive; and 455 (76%) were collected during the pandemic period from December 2019 to October 2020, consisting of 88 ANA-positive, 340 viralinfected or positive for antibodies other than SARS-CoV-2, and 27 bacterial or parasite antibody-positive.

The diagnostic performance of SARS-CoV-2 bAb assays is described in Table 3 . The diagnostic sensitivity of the CLIAs ranged from 54.2 to 56.6%, with no significant difference between the assays (p > 0.05). The sensitivity of the LFIAs ranged from 56.3 to 64.3%, showing a significant difference between SDF and P4D (p = 0.0279). SDF showed the highest sensitivity among the six assays, which was significantly different from all the other assays except SDQ. The diagnostic specificity of the CLIAs ranged from 98.2 to 99.8%, with a significant difference between Roche and Siemens (p = 0.0061). The specificity of the LFIAs ranged from 97.3% to 99.0%, without any significant difference between the assays. There was no significant difference in the pooled sensitivity and specificity between CLIAs and LFIAs. The Roche had the highest PPV (84.9%), whereas the SDQ had the lowest (28.5%). The NPV of each assay was comparable, ranging from 99.2% to 99.4%. The accuracy of the CLIAs ranged from 97.5% to 99.1%, and that of the LFIAs ranged from 96.7% to 98.3%.

The relatively strong and weak bands observed in SDQ and P4D were interpreted as distinctively positive and trace bands, respectively, by visual observation, whereas those in SDF were presented as index values using the fluorescencebased automated analyzer. Three observers reached a consensus through discussion of the trace bands observed in the SDQ and P4D. We compared the SDF index values between distinct positive and trace bands in SDQ and P4D according to the antibody type ( and ≥ 29 days, 2 (2.9%) sera. In the symptomatic group, the sensitivities of all six serological assays increased over 80% > 14 days after symptom onset. In the asymptomatic group, the sensitivities of both SDF and SDQ reached over 80% 8-14 days after initial RT-PCR detection, while those of the other assays reached over 80% > 21 days. In LFIAs, in the first 2 weeks of illness, the sensitivity of IgM was higher than that of IgG. The sensitivity of IgG began to exceed that of IgM after 15 days and was completely reversed after over 29 days for all LFIAs. A total of 385 samples from 196 COVID-19-positive patients were evaluated using the SARS-CoV-2 sVNT (Table 3 and Figure 1F ). The sVNT quantifies the inhibitory activity of the RBD-targeting nAbs, and the result is expressed as percentage inhibition (%I) = [1 -(sampled optical density value/negative control optical density value)] × 100. The median value of the nAb inhibition activity of the total COVID-19 samples was 44.3%. The median inhibition activity was significantly higher in the symptomatic group than in the asymptomatic group (50.0% vs. 29.2%; p < 0.0001). At 1-7 days after symptom onset, 32.3% were positive, with a median inhibition activity of 20.3% (cut-off: 30%). At 8-14 days, 64.6% were positive, with a median inhibition activity of 46.8%. At 15-21 days, 94.9% were positive, with a median inhibition activity of 85.2%. At 22-28 days, 96.3% were positive, with a median inhibition activity of 89.5%. After ≥ 29 days, the positive rate was 96.0%, and the inhibition activity was 81.0%.

The specificities of the three CLIAs and three LFIAs in COVID-19-negative samples are described in Table 3 . The overall falsepositive rate of the CLIAs ranged from 0.2 to 1.8%, and that of the LFIAs ranged from 0.2 to 2.7%. Among a total of 599 COVID-19-negative samples, a total of 34 samples were found to be false-positive for at least one of six serologic assays (Supplementary Table 2) . Of those 455 COVID-19negative samples collected during the pandemic period, 27 showed false-positive (5.9%). Of those 144 COVID-19-negative samples collected in the pre-pandemic period, seven showed false-positive (4.9%). Fisher's exact test showed no significant difference in proportions between the two groups (p = 0.8363). Among the 34 discordant (false-positive) samples, 20 (58.8%) showed false-positive results in one assay, 11 (32.4%) in two assays, and 3 (8.8%) in three assays. For CLIAs, the three false-positive results using the Abbott were weakly positive, so was the single false-positive result using the Roche. The 11 false-positive results obtained using the Siemens exhibited a wide range of positivity, from weak to strong. For LFIAs, IgM demonstrated more false-positive results than IgG. Using SDF, 42.9% (6/14) of the false-positive results were weakly positive. Using SDQ, 87.5% (14/16) were weakly positive (trace band), and using P4D, 83.3% (5/6) were weakly positive (trace band). To validate the 34 false-positive samples, we performed additional sVNT, except for one sample (No. 608) due to insufficient sample volume. Among the 33 validated samples, only one (sample No. 501) was weakly positive for sVNT (cut-off: 30% inhibition). The sample No. 501, positive only for SDF-IgG, had an ANA-positive feature and was obtained during the prepandemic period. 

The overall/positive/negative percent agreement, Cohen's κvalues, and McNemar's test of asymmetry between the six SARS-CoV-2 antibody assays are presented in Table 5 and Supplementary 

Kinetic analysis of symptomatic COVID-19 patients who demonstrated seroconversion based on the quantitative results of CLIA, SDF-IgM/IgG, and sVNT was performed (Figure 2) . The median TTPs were as follows in the ascending order: 7.7 days for SDF-IgM, 8.8 days for sVNT, 9.2 days for Siemens and SDF-IgG, 9.7 days for Abbott, and 9.8 days for Roche. In addition, TTP for each assay was also analyzed in the asymptomatic group. The median TTPs were as follows in the ascending order: 7.2 days for sVNT (patient n = 3), 7.5 days for SDF-IgG (patient n = 3), 8.8 days for SDF-IgM (patient n = 2), 9.6 days for Roche (patient n = 4), 10.2 days for Siemens (patient n = 2), and 10.6 days for Abbott (patient n = 3).

The quantitative results of the three CLIAs, SDF-IgM/IgG, and sVNT acquired from COVID-19-positive samples were used to analyze the correlation between assays (Figure 3) . The results showed a strong correlation between sVNT and other assays, with the Spearman ρ-values ranging from 0.746 (sVNT vs. SDF-IgM) to 0.854 (sVNT vs. Siemens).

To the best of our knowledge, this is the most extensive single-center evaluation of SARS-CoV-2 antibody tests in Korea, assessing the diagnostic performance of six different SARS-CoV-2 bAb assays and the activity and kinetics of neutralizing antibodies in a large set of COVID-19 samples. Several SARS-CoV-2 antibody assays have been developed and evaluated. However, owing to the variable factors affecting diagnostic accuracy, the clinical implications remain uncertain. The reported performance of antibody assays varies widely by factors such as the size of patients or samples, the type of analytical method, the type of antigen, the population used as the control samples, or the timing of sample collection (Lisboa Bastos et al., 2020; Chvatal-Medina et al., 2021; Jarrom et al., 2022) . Recently, a meta-analysis reported that the sensitivity of antibody tests using CLIAs ranged from 48.1 to 100%, and that of LFIAs ranged from 14.4 to 100% (Lisboa Bastos et al., 2020) . In our study, the pooled sensitivity of CLIAs was 55.4%, and that of the LFIAs was 56.1%, with no significant difference between the two groups. Among the CLIAs, the Abbott was used to detect IgG, and there was no significant difference in the IgG detection rate between CLIAs and LFIAs. Among the LFIAs, the sensitivity of the combination of IgM and IgG was higher than that of each Ig class, consistent with findings from previous studies Yun et al., 2021) . Other studies have also recommended measuring both IgM and IgG in the first days of illness to reduce the risk of false-negative results, which may be due to dynamic antibody titer changes (Krajewski et al., 2020; Sun et al., 2020) .

We analyzed the PPV, NPV, and accuracy with the rate of the accumulated confirmed cases (1.7%) in Korea. The PPV of Roche and Abbott was similar to the results of Park et al. (2022) , who calculated the PPV using several exemplary COVID-19-prevalent populations. The PPV of Siemens was relatively lower than that of other CLIAs, with lower specificity compared to previous findings (Florin et al., 2021; Yun et al., 2021; Park et al., 2022) . As the CLIAs for the SARS-CoV-2 antibody are not routinely used in our laboratory work, the reagent evaluation for this study was performed only for a short period. Therefore, insufficient optimization of the analytical system might be one reason for the poor performance (Kumleben et al., 2020; Ye et al., 2021) .

Usually, the LFIA result appears in color-changing bands interpreted by visual inspection, which can easily be influenced by the observer's experience and subjectivity. Those ambiguous bands would be a critical issue in using LFIAs for SARS-CoV-2 antibody detection because reclassifying trace bands as "negative" can change the test performance, as shown in our analysis ( Table 4) . A previous study underlined the importance of seropositive threshold determination, observer training, and LFIA analytical tools such as digital image analysis to improve objectivity (Whitman et al., 2020) .

As reported in previous studies, our results showed that the antibody detection rate of the symptomatic group increased over 80% > 14 days after symptom onset in all assays (Sun et al., 2020; Nicholson et al., 2021; Yun et al., 2021) . However, the rate in the asymptomatic group reached over 80% > 21 days after initial RT-PCR detection. This result might be due to the proportion difference in the early (1-7 days) stages of illness between the two groups. According to the Korean government's rapid COVID-19 response system, the asymptomatic COVID-19 patients were generally confirmed through contact tracing; hence, the early stage proportion would be higher [ Table 3 : 30.5% (98/321) vs. 69.1% (47/68)]. Another explanation could be that a lower viral load in asymptomatic individuals leads to a lower seropositivity rate, as reported by Wellinghausen et al. (2020) .

Additionally, we identified the primary RT-PCR cycle threshold (Ct) values tested at CNUH for 148 of the 158 symptomatic patients and 34 of the 41 asymptomatic patients. The Ct values of both the envelope (E) and RNA-dependent RNA polymerase (RdRp) genes revealed approximately one cycle bias between the symptomatic and asymptomatic groups with no significant difference [E gene: mean ± SD, 24.44 ± 6.38 vs. 23.43 ± 5.64, p = 0.4064; RdRp gene: 25.33 ± 6.22 vs. 24.35 ± 5.38; p = 0.4495 (data not shown)]. However, since one cycle difference in PCR suggests twice the viral load, we could assume that the viral load of asymptomatic patients might be only about half of that of symptomatic patients in this study.

A previous study on false-positive results of SARS-CoV-2 antibody tests in samples stored before the pandemic reported that the false-positive rate of the LFIAs was higher than that of the ELISAs (1.8% vs. 0.6%) (Latiano et al., 2021) . This was consistent with our results, in which the overall false-positive rates of the LFIAs were of a more expansive range than those of the CLIAs ( Table 3) . A large portion of the false-positive results was weak or trace, and the additionally performed sVNT was negative, except for in one sample collected in the prepandemic period. Among a total of 455 samples collected in the pandemic period, 9, 12, and 4 were found to be false positive for SDF-IgM/IgG, SDQ-IgM/IgG, and P4D-IgM/IgG, leading to assay specificities of 98.0, 97.4, and 99.1%, respectively. A comparative analysis for specificity, sensitivity, PPV, and NPV of all three LFIAs for varying seroprevalences (1, 5, and 10%) of SARS-CoV-2 antibody was shown in Supplementary Table 4 . At seroprevalence of 10%, all LFIAs had unsatisfactory or acceptable PPVs of 78.3, 72.2, and 87.7% for SDF-IgM/IgG, SDQ-IgM/IgG, and P4D-IgM/IgG, but at seroprevalence of 1%, these values dropped to unacceptably low levels of 24.7, 19.1, and 39.3 for SDF, SDQ, and P4D. However, at varying seroprevalence of 1, 5, and 10%, NPVs ranging from 95.3 to 99.6% were acceptably high levels. Collectively, these findings suggest that LFIA tests may be useful in a high seroprevalence setting, in which COVID-19 is widely spread.

In SARS-CoV-2 antibody testing, false-positive results (non-specific or cross-reactive) can arise from endogenous factors such as rheumatoid factors, heterophil antibodies, lysozymes, complements, other cross-antigens (e.g., similar epitopes between SARS-CoV-2 and other human coronaviruses), or exogenous interferences such as inadequate specimen quality and unsatisfactory test kit optimization (Ye et al., 2021) . A previous study in sub-Saharan Africa showed that pre-pandemic plasma samples, which either had the S proteins of HCoV-OC43, HCoV-HKU-1, HCoV-NL63, and HCoV-229E or the N proteins of HCoV-NL63, and HCoV-229E, were serological cross-reactive against the S and N proteins of SARS-CoV-2 (Tso et al., 2021) . Previous studies have also reported cross-reactivity with autoantibodies such as ANA and other viral infections such as cytomegalovirus (Jääskeläinen et al., 2020 ; Nicholson et al., 2021) . In practice, false-positive cases are difficult to rule out; therefore, test subjects should be selected wisely, recognizing the limitations of serological tests when applying them to asymptomatic, healthy subjects with no history of SARS-CoV-2 exposure (Latiano et al., 2021) .

In the agreement rate analysis, all assays showed good agreement. Among the CLIAs, the Abbott vs. Roche comparison had a higher agreement rate than the Siemens vs. Abbott or Roche comparison, consistent with other studies (Yun et al., 2021; Park et al., 2022) . This result might be due to the difference in the target protein-Abbott and Roche target an epitope of the N protein, and Siemens targets the S protein. Among the LFIAs, SDF-IgG and SDQ-IgG showed the highest agreement rates, likely because both assays are from the same manufacturer and target the same IgG.

The sVNT test indirectly detects the function of neutralizing SARS-CoV-2 antibodies that block the interaction between the viral spike RBD and the host ACE2 receptor. The positive rate of sVNT in sera collected > 14 days after symptom onset was similar to previous findings (Tan et al., 2020; Nicholson et al., 2021; Yun et al., 2021) . Interestingly, the symptomatic group showed higher inhibition activity than the asymptomatic group, although the positive rate was reversed (Table 3 and Figure 1F ). These data might align with the statement that the asymptomatic group consisted of a higher proportion of early stage illnesses and might have a lower viral load (Wellinghausen et al., 2020) . However, this could be due to the sample size imbalance (8 vs. 112) between asymptomatic and symptomatic groups at that time frame (≥15 days category), requiring a further study using more sample size of asymptomatic cases. In our study, the bAb IgM assay showed the earliest seroconversion at 7.7 days, followed by the nAb IgG assay at 8.8 days and the bAb IgG assay at 9.2-9.8 days, which supports previous data for the utility and clinical importance of using IgM antibodies for SARS-CoV-2 diagnosis (Ng et al., 2020; Orner et al., 2021) . The index values of the three CLIAs and SDF-IgM/IgG vs. sVNT percentage inhibition were strongly correlated (Figure 3) , and the use of the same target protein could Correlation between two measures was performed using Spearman ρ (95% confidence interval). The horizontal and vertical dotted lines indicate the cut-off value of each assay. Abbott, SARS-CoV-2 IgG (Abbott); COI, cut-off index; %I, percentage inhibition; Roche, Elecsys Anti-SARS-CoV-2 (Roche); S/C, sample/calibrator; S/CO, sample/cut-off; SDF, STANDARD F COVID-19 IgM/IgG Combo FIA (SD BIOSENSOR); Siemens, ADVIA Centaur SARS-CoV-2 Total (Siemens); sVNT, surrogate virus neutralization test. explain the strongest correlation between Siemens and sVNT (Yun et al., 2021) .

Our study had some limitations. First, the negative samples were from patients in the pre-pandemic and pandemic periods who had no history of COVID-19 or epidemiological relationship with COVID-19. They did not undergo additional PCR confirmation. Nevertheless, reflecting the government's strict response policy to COVID-19 and the low disease prevalence of COVID-19 at that time in Korea, the samples from patients with no history of COVID-19 or any epidemiological relationship with COVID-19 could be considered COVID-19-negative. Second, false-negative (or even undetected) results cannot be ruled out due to the possibility of insufficient optimization of the assay systems, as we evaluated the assays only for a short period. Finally, we only proposed the fragmentary kinetics of the antibodies detected in this study. Because the samples used in this study were serum remnants from blood samples retrieved for routine laboratory tests, the multiple samples from one patient were serially collected at different time points (one or two samples per week) but having irregular time intervals, providing only estimated TTPs for individual patients calculated by interpolating the positive cut-off line to the curve using the 4PL equation. Moreover, the SARS-CoV-2 antibody response is correlated with various factors, including primary infection or reinfection of COVID-19, symptom onset, disease severity, fever, age, and sex (Schlickeiser et al., 2021) . As the national contact tracing system was widely and strictly applied to all patients from the beginning of the pandemic period in Korea, the contact history with COVID-19 patients in this study were thoroughly investigated through the contact tracing system. As a result of the analysis, all of these patients had a current but no previous contact history with COVID-19 patients in the pandemic period, indicating that all of our patients had a primary infection, not re-infection. In addition, we analyzed the difference of antibody kinetics between symptomatic and asymptomatic groups. However, the sample size of the asymptomatic group was too small to calculate the p-values. More serial follow-up data and large-sized samples from well-evaluated individuals may be needed for intense antibody kinetic analyses.

In conclusion, our study offers a detailed comparison of three CLIAs, three LFIAs, and an sVNT assay. With the initiation of vaccines administration, routine antibody test for COVID-19 has been started in general laboratories all over the world. Therefore, to choose the most suitable serological assays for a particular laboratory environment and situation, it is necessary to understand the characteristics of each assay. The interpretation of antibody assay results should also be performed with caution. The patient's contact history, symptoms, the time of illness, measured assays, target antibodies, and the antigens used should also be considered. In particular, for LFIAs, it is recommended that more objectively interpreted assays are used, and a band interpretation system should be established for each laboratory with sufficient observer training. We also expect that routinely available sVNT will play an essential role in the laboratory where nAb testing is desired.

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

The studies involving human participants were reviewed and approved by the Institutional Review Board (IRB) of CNUH (IRB No. CNUH-2020-223) . Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

H-WC, SYL, and S-JKe designed the study, analyzed, and discussed the data. H-WC, C-HJ, S-JKa, EJW, and SYL generated the data. H-WC and SYL ran the statistical analysis. H-WC and S-JKe wrote the primary manuscript. All authors were involved in writing and had final approval of the submitted and published versions of the manuscript.

This research was supported by the National Research Foundation of Korea (2020R1C1C1007297 and 2021R1A2C2013961), Chonnam National University Hospital Biomedical Research Institute (BCRI21020), and Biomedical Research Institute of Jeonbuk National University Hospital. The funding organizations played no role in the study's design, choice of enrolled patients/specimens, review and interpretation of data, preparation of the manuscript, or final approval.

Quest Graph TM Four Parameter Logistic (4PL) Curve Calculator

Transmission characteristics of SARS-CoV-2 that hinder effective control

Multicenter evaluation of two chemiluminescence and three lateral flow immunoassays for the diagnosis of COVID-19 and assessment of antibody dynamic responses to SARS-CoV-2 in Taiwan

Antibody Responses in COVID-19: a

Performance evaluation of the siemens SARS-CoV-2 total antibody and IgG antibody test

Improved detection of antibodies against SARS-CoV-2 by microspherebased antibody assay

List of COVID-19 in Vitro Diagnostic Devices Officially Approved by MFDS

Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation

Effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review

Neutralization of virus infectivity by antibodies: old problems in new perspectives

Coronavirus Disease-19 Main Website

Update on serologic testing in COVID-19

Test, test, test for COVID-19 antibodies: the importance of sensitivity, specificity and predictive powers

Spearman's Rank-Order Correlation. Statistical Tutorials and Software Guides

False-positive results of SARS-CoV-2 IgM/IgG antibody tests in sera stored before the 2020 pandemic in Italy

Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis

Interrater reliability: the kappa statistic

Ministry of Food and Drug Safety White Paper

SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood

Evaluation of 6 commercial SARS-CoV-2 serology assays detecting different antibodies for clinical testing and serosurveillance

Comparison of SARS-CoV-2 IgM and IgG seroconversion profiles among hospitalized patients in two US cities

Performance comparison of five SARS-CoV-2 antibody assays for seroprevalence studies

Side-by-Side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity

Structural proteins in severe acute respiratory syndrome coronavirus-2

Disease severity, fever, age, and sex correlate with SARS-CoV-2 neutralizing antibody responses

IgG Seroprevalence of COVID-19 among individuals without a history of the coronavirus disease infection in Daegu

Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine

A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction

High prevalence of pre-existing serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

CoV-2-IgG response is different in COVID-19 outpatients and asymptomatic contact persons

Evaluation of SARS-CoV-2 serology assays reveals a range of test performance

Characteristics of and important lessons from the coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention

Potential false-positive reasons for SARS-CoV-2 antibody testing and its solution

Comparison of SARS-CoV-2 antibody responses and seroconversion in COVID-19 patients using twelve commercial immunoassays

AACC practical recommendations for implementing and interpreting SARS-CoV-2 emergency use authorization and laboratory-developed test serologic testing in clinical laboratories

The reagents were provided in-kind: SARS-CoV-2 IgG by Abbott, Elecsys Anti-SARS-CoV-2 by Roche, ADVIA Centaur SARS-CoV-2 Total by Siemens, STANDARD F COVID-19 IgM/IgG Combo FIA and STANDARD Q COVID-19 IgM/IgG Combo by SD Biosensor, and P4DETECT COVID-19 IgG/IgM by PRIME4DIA.

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.